Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP raised its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 63.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 179,687 shares of the biotechnology company’s stock after purchasing an additional 70,008 shares during the quarter. Two Sigma Investments LP owned about 0.12% of Ironwood Pharmaceuticals worth $1,862,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc raised its holdings in shares of Ironwood Pharmaceuticals by 3.2% during the 3rd quarter. Vanguard Group Inc now owns 12,324,954 shares of the biotechnology company’s stock valued at $227,518,000 after purchasing an additional 377,177 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 3.2% during the 3rd quarter. Vanguard Group Inc. now owns 12,324,954 shares of the biotechnology company’s stock valued at $227,518,000 after purchasing an additional 377,177 shares in the last quarter. MFN Partners Management LP bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter valued at $51,174,000. Westfield Capital Management Co. LP raised its holdings in shares of Ironwood Pharmaceuticals by 5.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,974,879 shares of the biotechnology company’s stock valued at $20,460,000 after purchasing an additional 96,070 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Ironwood Pharmaceuticals by 2.0% in the 4th quarter. Northern Trust Corp now owns 1,712,129 shares of the biotechnology company’s stock worth $17,738,000 after acquiring an additional 33,007 shares during the period. Institutional investors own 97.05% of the company’s stock.

Several brokerages recently commented on IRWD. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, April 16th. Credit Suisse Group set a $16.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, March 22nd. Wood & Company began coverage on shares of Ironwood Pharmaceuticals in a report on Tuesday, February 26th. They issued a “buy” rating on the stock. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average target price of $16.15.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 275,000 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $13.26, for a total value of $3,646,500.00. Following the transaction, the insider now directly owns 577,980 shares in the company, valued at $7,664,014.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence S. Olanoff sold 2,000 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $14.41, for a total transaction of $28,820.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 373,872 shares of company stock worth $4,902,158. Company insiders own 7.63% of the company’s stock.

Shares of Ironwood Pharmaceuticals stock traded down $0.06 during trading on Wednesday, hitting $11.94. 884,011 shares of the company’s stock traded hands, compared to its average volume of 1,462,433. Ironwood Pharmaceuticals, Inc. has a twelve month low of $9.07 and a twelve month high of $21.20. The firm has a market cap of $1.74 billion, a P/E ratio of -12.57 and a beta of 1.91.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Wednesday, February 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.15. The business had revenue of $130.70 million for the quarter, compared to analyst estimates of $96.57 million. During the same quarter last year, the firm posted ($0.14) earnings per share. Ironwood Pharmaceuticals’s revenue was up 38.7% on a year-over-year basis. Sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post -0.02 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by Two Sigma Investments LP” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/24/two-sigma-investments-lp-raises-holdings-in-ironwood-pharmaceuticals-inc-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

See Also: How do taxes affect a CDs total return?

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.